Sensitivity to idasanutlin treatment appeared to be limited to AML subgroups characterized by MDM2 overexpression, whereas idasanutlin resistance was observed in AML subgroups characterized by MDMX overexpression [20]. This evidence concerns the gene MDM2 and acute myeloid leukemia.